BMO reiterates Trevi Therapeutics stock rating after rival study fails

BMO Capital reiterated Outperform on Trevi Therapeutics with a $36 price target, about 168% above the cited $13.42 share price, after competitor Nocion’s Phase 2b ASPIRE study failed its primary endpoint. BMO cited Trevi’s Haduvio as differentiated, while Trevi expects a LAKE study sample-size re-estimation in Q4 2026 and multiple clinical readouts in H2 2027. Offsetting considerations include a slightly wider-than-expected Q2 2026 loss of $0.11 per share versus a $0.10 forecast and an InvestingPro assessment that the shares appear overvalued relative to fair value.

Analysis

The competitor’s failure improves TRVI’s relative positioning only if Haduvio’s own data show a reproducible signal; one negative trial does not validate Trevi’s mechanism or establish that the market is available to it. The non-obvious read-through is also methodological: a large, variable placebo response raises the risk that cough-frequency endpoints produce noisy results across the category, potentially increasing trial sizes, timelines, and capital needs even for a differentiated candidate. Trevi’s stated cash runway reduces near-term financing pressure, but should be reassessed against the LAKE sample-size decision and the cost of its broader clinical program.

Near term, the Q4 2026 LAKE re-estimation is the key catalyst: continuation without changes would reduce one execution concern; a larger enrollment requirement could be directionally encouraging on efficacy while still worsening time and cost. The larger value inflection remains the 2027 readouts, so the competitive headline alone is a weak basis for chasing a sharp move. Over 6–18 months, successful data could support differentiation across cough indications; disappointing or noisy data would expose the stock to binary downside, regardless of competitor setbacks. Analyst targets and the cited fair-value estimate are not substitutes for clinical evidence.

Key Decisions for Investors

• Do not treat Nocion’s result as proof of Haduvio efficacy. Consider only a small, staged TRVI position for investors able to tolerate clinical-trial downside; avoid adding solely on the competitor headline.
• Use the Q4 2026 LAKE sample-size re-estimation as the next decision point. Verify whether the recommendation reflects efficacy/futility criteria, the added enrollment required, and the resulting timeline and cash-burn impact before increasing exposure.
• Falsification triggers: a recommendation to stop or materially redesign LAKE, materially weaker Haduvio efficacy or safety data, or guidance indicating that trial expansion compresses the stated cash runway. A larger trial is not automatically bullish if it mainly reflects uncertainty or endpoint noise.
• Monitor the 2027 readouts for prespecified cough-frequency results and consistency across indications. Until those data arrive, the risk/reward is catalyst-driven and should not be underwritten as a durable competitive win.